AzTrials
AzTrials

Post StrokeNCT03751306

Aerobic Exercise and Transcranial Low Laser Therapy in Patients With Central Nervous System Injury

A study testing Transcranial Photobiomodulation and Cardiorespiratory Rehabilitation in people with Post Stroke and Post-Traumatic Headache, run by Universidade do Vale do Paraíba at 1 site in Brazil.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Objective of this protocol will be to evaluate the parameters related to the function of the musculoskeletal and cardiorespiratory system, through a rehabilitation and training program for people with acquired central nervous system and multiple sclerosis. Read more about this study

Who is it for?
Ages 18 to 85 years
What is being tested?
Transcranial Photobiomodulation and Cardiorespiratory Rehabilitation
Type of treatment
Surgery or procedure
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
90 participants
Where
1 siteBrazil
Study dates
14 Jan 2019to 5 Mar 2020
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Persons with stroke, traumatic brain injury, spinal cord trauma, post-operative brain tumor, chronic non-progressive encephalopathy and multiple sclerosis;
  • Chronic neurological diseases, from 6 months of injury;
  • Caucasian individuals;
  • Age between 18 and 85 years;
  • Both sexes;
  • Individuals with the cognitive preserved;
Show all 9Show fewer
  • Persons who are able to wander on the treadmill voluntarily or through assistance from the Rehabilitation and Physical Activity Station BrainMov®;
  • Persons who make continuous and regular use of medications prescribed by the physician for the control and / or treatment of chronic diseases;
  • People with the release of the cardiologist for rehabilitation.

Who cannot join

  • People who do not meet the inclusion criteria;
  • Active smokers;
  • Carriers of chronic respiratory diseases, such as COPD, asthma and bronchiectasis;
  • Patients with decompensated heart disease;
  • Obesity grade II - body mass index greater than 34.99 kg / m2;
  • Patients with spinal cord injury above T6, who present autonomic dysreflexia;
Show all 10Show fewer
  • Patients with ASA A or B spinal cord injury;
  • Patients with multiple sclerosis who are in an outbreak period;
  • Patients taking betablockers;
  • Hemorrhagic stroke.

Trial locations and contacts

1 site in 1 country.

Carolina Lobo Guimarães contact

55 12 981585974

caroll.guimaraes@yahoo.com.br

Brazil1 site
  • Universidade do Vale do Paraíba

    São José dos Campos, São Paulo, 12244-000

    Ana Paula Pinto, 55 12 981585974, apaula@outlook.com.br

Other trials in Brazil

About this study

Official title: Sensory-Motor and Cardiorespiratory Rehabilitation Associated With Transcranial Laser Therapy in Patients With Central Nervous System Injury

Objective of this protocol will be to evaluate the parameters related to the function of the musculoskeletal and cardiorespiratory system, through a rehabilitation and training program for people with acquired central nervous system and multiple sclerosis. The study will consist of volunteers with acquired CNS lesions and multiple sclerosis of both sexes, between 18 and 85 years old, and who wander with or without aid devices, randomly divided into 3 groups: Group 1 (cardiopulmonary treatment), Group 2 (cardiopulmonary treatment and transcranial photobiomodulation application) and Group 3 (cardiopulmonary treatment and placebo laser). All groups will receive aerobic training on a treadmill (Moviment®) with the aid of a suspension equipment (BrainMov® Physical Activity Station). The transcranial photobiomodulation (laser diode, λ = 810 nm, beam area 0.028 cm², power of 100 mW, power density of 3.5 mW / cm², energy of 3 Joules / point and energy density of 107.1 J / cm2) will be applied on the skin / scalp and the International System 10-20 at points F7, F8 and AFz will be used as reference for irradiation. Muscular activation, heart rate variability, lung volumes and capacities, fatigability, exercise tolerance, cognition and quality of life will be evaluated before, during, at the end and after two months of rehabilitation. The treatment proposed in this study, using transcranial photobiomodulation, is expected to improve muscle, sensory, cardiorespiratory, cognitive functions and to interfere positively in the quality of life of the volunteers.

Read the detailed description

Central nervous system (CNS) diseases can be acquired (such as stroke, spinal cord injury, and traumatic brain injury) or non-acquired (such as multiple sclerosis). Many diseases that affect the CNS can be fatal or cause sequelae, which affect the sensorimotor, cardiorespiratory and the quality of life of the individual. Subjects with neurological lesions present low resistance to exercise, a factor that can be attributed to decreased muscle recruitment, oxidative and metabolic capacity reduction, low aerobic resistance and increased energy expenditure. With that in mind, treatment proposals such as aerobic training and gait training with or without weight loss can maximize and restore the individual's functional abilities through active learning. Cardiorespiratory fitness in this patient profile has benefits in terms of fatigue retardation, gait improvement and regulation of the autonomic nervous system. Aerobic exercises change the heart rhythm, increase vascularity and provide oxygen. The association of these factors promote cerebral neuroprotective effect, stimulate the production of endogenous neutrotransmitters related to general well-being and favor neuroplasticity. Low-intensity laser therapy, especially transcranial photobiomodulation, has shown benefits in animals and humans such as cognitive and memory improvement, improvement in the behavioral picture, such as attenuation of depression and anxiety, and cortical oxygenation.

The study design is a randomized, double-blind, placebo-controlled trial that will compare the effect of cardiorespiratory rehabilitation, cardiorespiratory rehabilitation and low-intensity laser therapy, cardiorespiratory rehabilitation and placebo laser. It is worth mentioning that the use of a Placebo Therapy is restricted to Low Power Laser irradiation. This means that the three experimental groups will effectively be treated with cardiorespiratory rehabilitation, a therapy that improves physical fitness. The treatment with transcranial photobiomodulation irradiation aims to verify the effects and aggregates greater beneficial to the volunteers. In this case, the magnitude of the laser effect must be calculated by the difference (if any) of the group treated with "cardiorespiratory rehabilitation + laser" subtracted from the group treated with "cardiorespiratory rehabilitation + laser Placebo".

Being tested
Transcranial Photobiomodulation, Transcranial Photobiomodulation (Placebo), Cardiorespiratory Rehabilitation
Keywords
Neurological Diseases, Cardiorespiratory Rehabilitation, Aerobic exercise, Fotobiomodulação Transcraniana
Medical subject headings
Post-Traumatic Headache, Spinal Injuries, Cerebral Palsy, Multiple Sclerosis, Muscle Spasticity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transcranial PhotobiomodulationProcedure or surgery

    Photobiomodulation Rehabilitation:

    Diode laser, λ infrared = 810 nm, 0.028 cm2 beam area, 100 mW power, 3.5 W / cm2 power density, 3 Joules / dot and Energy Density of 107.1 J / cm2). Each point will be radiated for 30 seconds. The regions of irradiation will be in the middle cerebral arteries (points F7 and F8 will be used as reference point according to the International System 10-20 of the electroencephalogram) and anterior cerebral artery (AFz point according to the International System 10-20 of the electroencephalogram) .

  • Transcranial Photobiomodulation (Placebo)Procedure or surgery

    Photobiomodulation Placebo Therapy:

    The same apparatus of the transcranial group photobiomodulation and the same irradiation points will be used. However, during the procedure, with the laser off.

  • Cardiorespiratory RehabilitationProcedure or surgery

    Cardiorespiratory Rehabilitation:

    Aerobic training on the treadmill will be reliated for 30 minutes using the support of the Rehabilitation and Physical Activity Station BrainMov® (equipment with 4 pillars condition that favors the suspension and stabilization of people with neuromuscular dysfunctions of mild to severe impairment. For monitoring, the training heart rate equation - Karvonen equation, effort perception scale - BORG, systemic arterial pressure, peripheral oxygen saturation, and patient signs and symptoms will be used. Subsequently, respiratory exercises and muscle strengthening of lower limbs, final relaxation and general guidelines will be performed for research volunteer and his / her relatives.

Study groups in NCT03751306
Study groupRoleWhat they receive
Control-Cardiorespiratory RehabilitationActive comparatorThese individuals will compose the control group for transcranial laser therapy, which will only receive cardiorespiratory rehabilitation.
Receives: Procedure: Cardiorespiratory Rehabilitation
Transcranial Photobiomodulation PlaceboPlacebo comparatorIn this group, the application of laser irradiation will be simulated, and the laser will be turned off. And the simulation of irradiation, the individuals will initiate cardiorespiratory rehabilitation.
Receives: Procedure: Transcranial Photobiomodulation (Placebo); Procedure: Cardiorespiratory Rehabilitation
Transcranial PhotobiomodulationExperimentalIn this group, low-intensity irradiation will be applied and after irradiation, the volunteers will begin cardiorespiratory rehabilitation.
Receives: Procedure: Transcranial Photobiomodulation; Procedure: Cardiorespiratory Rehabilitation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in Muscular electrical activity (Surface electromyograph).

    The surface electrodes will be positioned in the rectus femoris and femoral biceps muscles. The evaluation of the muscles will be realized during the squat movement. 10 seconds of signal collection (in triplicate).

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  2. Change in analysis of bipodal balance during the squat movement.

    The balance evaluation will be performed during the squat movement on the power platform (Stabilometric analysis in Kgf). 10 seconds of signal collection (in triplicate).

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  3. Change in analysis of the heart rate variability to study the responses of the autonomic nervous system

    Heart rate variability will be assessed during aerobic training on the treadmill for 40 minutes (5 minutes of initial rest, 30 minutes of exercise and 5 minutes of final rest).

    Measured: Baseline (First day of rehabilitation) and after 9 weeks (Last day of rehabilitation).

  4. Change in Pulmonary function analysis (spirometry): forced vital capacity

    Using the spirometry technique, forced vital capacity (measured in liters) will be evaluated. The volunteer will be asked to perform the maximum inspiration and exhale with maximum effort.

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  5. Change in Pulmonary function analysis (spirometry): forced expiratory volume in the first second

    Using the spirometry technique, forced expiratory volume in the first second (measured in liters) will be evaluated. The volume of exhaled air in the first second in the forced vital capacity maneuver will be evaluated.

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  6. Change in Pulmonary function analysis (spirometry): Tiffeneau Index

    Using the spirometry technique, Tiffeneau Index will be evaluated. The Tiffeneau index is the result of the division of forced expiratory volume in the first second in relation to forced vital capacity.

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  7. Change in Pulmonary function analysis (spirometry): maximum voluntary ventilation

    Using the spirometry technique, maximum voluntary ventilation will be evaluated. Maximum voluntary ventilation is the largest volume of air that the individual can mobilize in one minute with maximum voluntary effort. The test gives an overview of the ventilatory function (measured in L / min).

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  8. Change in analysis of inspiratory muscle strength

    The inspiratory muscle strength will be evaluated by means of the manovacuometer.

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  9. Analysis of expiratory muscle strength

    The expiratory muscle strength will be evaluated by means of the manovacuometer

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  10. Change in analysis of Peak expiratory flow.

    To analyze the velocity of the air out of the lungs.

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  11. Change in analysis of the thoracic expandability (axillary level).

    In order to analyze the chest expansion at the axillary level, a metric tape placed at the torarico-axillary level will be used, which will measure the inspiratory and expiration mobility values, and will be subtracted (Insp-Exp).

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  12. Change in analysis of the thoracic expandability (xiphoid level).

    In order to analyze the chest expansion at the xiphoid level, a metric tape will be used, placed at the thoracic-xiphoid level, which will measure the inspiratory and expiration mobility values and then be subtracted (Insp-Exp).

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  13. Change in analysis of abdominal level expandability.

    In order to analyze abdominal expansibility, a tape measure will be used, placed at the level of the umbilical scar, which will measure the inspiratory and expiration mobility values and will be subtracted (Insp-Exp).

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  14. Change in analysis of change in Infrared Thermography.

    By means of an infrared thermographic camera, the blood circulation of the lower limbs will be evaluated by the temperature difference.

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  15. Change in aariation of blood lactate level.

    The blood lactate level will be measured by a lactometer, which will be collected from the volunteer's blood sample before starting the aerobic training on the treadmill and after training.

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  16. Change in 6-Minute Walk Test (Adapted)

    The 6-minute-walk test will be adapted for neurological patients, which will be evaluated for exercise tolerance using a treadmill (Moviment RT200®). Volunteers will be assisted by the BrainMov® Rehabilitation and Physical Activity Station to stabilize the trunk and thus remain upright to wander on the treadmill

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  17. Change in Mini-Mental State Examination (MINI MENTAL).

    To evaluate the cognitive functions, the MINI MENTAL test will be applied.

    Measured: Baseline (before starting rehabilitation) and after 9 weeks.

  18. Change in Short Form 36 questionnaire (SF-36)

    To evaluate the domains of quality of life: Functional Capacity, physical aspect, pain, general health, vitality, social aspect, emotional spectrum and mental health

    Measured: Baseline (before starting rehabilitation) and after 9 week.

Secondary outcomes (18)
  1. Follow-up: Evaluation Muscular electrical activity (Surface electromyograph)

    Evaluation of muscular electrical activity after 9 weeks of the end of rehabilitation. The surface electrodes will be positioned in the rectus femoris and femoral biceps muscles. The evaluation of the muscles will be realized during the squat movement. 10 seconds of signal collection (in triplicate).

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  2. Follow-up: Analysis of bipodal balance during the squat movement

    The balance evaluation will be performed during the squat movement on the power platform. 10 seconds of signal collection (in triplicate).

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  3. Follow-up: Analysis of the heart rate variability to study the responses of the autonomic nervous system

    The heart rate variability will be evaluated during aerobic training on the treadmill using a frequency for 5 minutes of initial rest, 30 minutes of exercise and 5 minutes of final rest.

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  4. Follow-up: Pulmonary function analysis (spirometry): forced vital capacity

    Using the spirometry technique, forced vital capacity (measured in liters) will be evaluated. The patient will be asked to perform the maximum inspiration and exhale with maximum effort.

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  5. Follow-up: Pulmonary function analysis (spirometry): forced expiratory volume in the first second

    Using the spirometry technique, forced expiratory volume in the first second (measured in liters) will be evaluated. The volume of exhaled air in the first second in the forced vital capacity maneuver will be evaluated.

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  6. Follow-up: Pulmonary function analysis (spirometry):Tiffeneau Index

    Using the spirometry technique, Tiffeneau Index will be evaluated. The Tiffeneau index is the result of the division of forced expiratory volume in the first second in relation to forced vital capacity.

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  7. Follow-up: Pulmonary function analysis (spirometry): maximum voluntary ventilation

    Using the spirometry technique, maximum voluntary ventilation will be evaluated. Maximum voluntary ventilation is the largest volume of air that the individual can mobilize in one minute with maximum voluntary effort. The test gives an overview of the ventilatory function (measured in L / min).

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  8. Follow-up: Analysis of inspiratory muscle strength

    The inspiratory muscle strength will be evaluated by means of the manovacuometer.

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  9. Follow-up: Analysis of expiratory muscle strength

    The expiratory muscle strength will be evaluated by means of the manovacuometer.

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  10. Follow-up: Analysis of Peak expiratory flow.

    To analyze the velocity of the air out of the lungs.

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  11. Follow-up: Analysis of the thoracic expandability (axillary level).

    In order to analyze the chest expansion at the axillary level, a metric tape placed at the torarico-axillary level will be used, which will measure the inspiratory and expiration mobility values, and will be subtracted (Insp-Exp).

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  12. Follow-up: Analysis of the thoracic expandability (xiphoid level).

    In order to analyze the chest expansion at the xiphoid level, a metric tape will be used, placed at the thoracic-xiphoid level, which will measure the inspiratory and expiration mobility values and then be subtracted (Insp-Exp).

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  13. Follow-up: Analysis of abdominal level expandability.

    In order to analyze abdominal expansibility, a tape measure will be used, placed at the level of the umbilical scar, which will measure the inspiratory and expiration mobility values and will be subtracted (Insp-Exp).

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  14. Follow-up: Analysis of change in Infrared Thermography.

    By means of an infrared thermographic camera, the blood circulation of the lower limbs will be evaluated by the temperature difference.

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  15. Follow-up: Variation of blood lactate level.

    The blood lactate level will be measured by a lactometer, which will be collected from the volunteer's blood sample before starting the aerobic training on the treadmill and after training.

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  16. Follow-up: Analysis 6-Minute Walk Test (Adapted)

    The 6-minute-walk test will be adapted for neurological patients, which will be evaluated for exercise tolerance using a treadmill (Moviment RT200®). Volunteers will be assisted by the BrainMov® Rehabilitation and Physical Activity Station to stabilize the trunk and thus remain upright to wander on the treadmill.

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  17. Follow-up: Evaluation Mini-Mental State Examination (MINI MENTAL).

    To evaluate the cognitive functions, the MINI MENTAL test will be applied.

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

  18. Follow-up: Evaluation Short Form 36 questionnaire (SF-36)

    To evaluate the domains of quality of life: Functional Capacity, physical aspect, pain, general health, vitality, social aspect, emotional spectrum and mental health

    Measured: The follow-up revaluation will be 2 months after the end of rehabilitation.

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 Nov 2018
  2. Study start14 Jan 2019 (estimated)
  3. Primary completion31 Jul 2019 (estimated)
  4. Study completion5 Mar 2020 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Sequential
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
90 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03751306
Sponsor's protocol ID
94858718.3.0000.5503
Status last verified
Nov 2018
First submitted
1 Nov 2018
Last updated
27 Nov 2018
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Pinto AP, Guimaraes CL, Souza GADS, Leonardo PS, Neves MFD, Lima FPS, Lima MO, Lopes-Martins RAB. Sensory-motor and cardiorespiratory sensory rehabilitation associated with transcranial photobiomodulation in patients with central nervous system injury: Trial protocol for a single-center, randomized, double-blind, and controlled clinical trial. Medicine (Baltimore). 2019 Jun;98(25):e15851. doi: 10.1097/MD.0000000000015851.

    PubMed 31232920

Questions about this trial

What is this clinical trial studying?

A study testing Transcranial Photobiomodulation and Cardiorespiratory Rehabilitation in people with Post Stroke and Post-Traumatic Headache, run by Universidade do Vale do Paraíba at 1 site in Brazil.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 27 Nov 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Brazil. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Ana Paula Pinto (55 12 981585974, apaula@outlook.com.br), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in Muscular electrical activity (Surface electromyograph). (time frame: Baseline (before starting rehabilitation) and after 9 weeks.). The study lists 18 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03751306, which also lists 1 linked publication.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Nov 2018.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in